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Abstract
Nanoparticles, with their selective targeting capabilities
and superior efficacy, are becoming increasingly important
in modern cancer therapy and starting to overshadow
traditional cancer therapies such as chemotherapy, radia‐
tion and surgery. ZnO nanoparticles, with their unique
properties such as biocompatibility, high selectivity,
enhanced cytotoxicity and easy synthesis, may be a
promising anticancer agent. Zinc, as one of the major trace
elements of the human body and co-factor of more than 300
mammalian enzymes, plays an important role in maintain‐
ing crucial cellular processes including oxidative stress,
DNA replication, DNA repair, cell cycle progression and
apoptosis. Thus, it is evident that an alteration in zinc levels
in cancer cells can cause a deleterious effect. Research has
shown that low zinc concentration in cells leads to the
initiation and progression of cancer and high zinc concen‐
tration shows toxic effects. Zinc-mediated protein activity
disequilibrium and oxidative stress through reactive
oxygen species (ROS) may be the probable mechanism of
this cytotoxic effect. The selective localization of ZnO
nanoparticles towards cancer cells due to enhanced
permeability and retention (EPR) effect and electrostatic
interaction and selective cytotoxicity due to increased ROS
present in cancer cells show that ZnO nanoparticles can
selectively target and kill cancer cells, making them a
promising anticancer agent.
Keywords Zinc Oxide (Zno), Anti-cancer Agent, Reactive
Oxygen Species (ROS), Selectivity, Cytotoxicity, Zinc-
mediated Protein Activity Disequilibrium, Enhanced
Permeation and Retention Effect (EPR)
1. Introduction
Cancer, a condition of uncontrolled cell differentiation, has
usually been treated by chemotherapy, radiation and
surgery during the past several decades [1]. These therapies
are certainly efficacious in the destruction of cancer cells,
but, alongside that, they come with the cost of an increasing
rate of adverse consequences due to unselective effects
directed towards normal cells as well [2]. These therapies
are now gradually becoming outdated in cancer treatment
due to the development of nanomedicine, targeted drug
delivery and multi-target inhibitors [3]. Nanomedicine is
the field of biomedical application of nanotechnology in
which engineered nanoparticles (NPs) are used to treat
disease. Nanomedicine, with its advanced imaging and
therapeutic capabilities, has the potential for early detec‐
tion of cancer and cancer treatment [4]. It has the additional
benefits of active/passive targeting, high solubility/
bioavailability, biocompatibility and multifunctionality
over traditional cancer therapies [5].
1Nanobiomedicine, 2016, 3:9 | doi: 10.5772/63437
Nanomaterials show the following unique properties, due
to which they have recently become a widely discussed
research topic and a preferable substitute to conventional
cancer treatment methodology: 1) Biomolecules, whose
size is comparable with nanoparticles, play an important
role in regulating various cellular cycles of the body and
maintaining crucial cellular homoeostasis. With proper
engineering, NPs can be localized in any system of the body
and mimic the activity of biomolecules, thus hacking the
system biology of the body according to the need for human
benefit. 2) NPs are highly soluble due to their small size and
their solubility can be further increased by proper surface
modification. 3) Due to NPs’ high surface area to volume
ratio, they have ample surface area to encapsulate drugs
and other materials, thus providing higher therapeutic
payload. 4) Due to their selective targeting nature, NPs can
specifically release a therapeutic payload onto the target,
reducing the side effects on normal cells [4, 5]. Besides
cancer, nanomedicine is now showing increasing applica‐
tion in personalized medicine [6] and diagnosis and
therapy of cardiovascular diseases [7].
The major aspect of nanomedicine comprises inorganic
NPs. Many inorganic NPs conjugated with anti-cancerous
drugs or bio-active molecules (peptides, proteins, DNA,
etc.) have already been approved by the U.S. Food and
Drug Administration (FDA) and European markets, such
as Feridex, Resovist, Doxil, Abraxane, etc. [4]. Furthermore,
inorganic NPs themselves show selective cytotoxicity
towards cancer cells [8]. Inorganic NPs such as iron oxide
NPs, titanium dioxide NPs, cerium oxide NPs, zinc oxide
NPs, copper oxide NPs, silica NPs, etc., are being widely
researched and used for anticancer therapy [9]. Each of
these nanoparticles has its own unique features, which
makes them a novel and efficient tool for anticancer
therapy. Iron oxide NPs conjugated with anticancer drugs
are used to make magneto-sensitive NPs for selective
targeting using magnetic fields in cancer treatment [10].
Likewise, titanium dioxide NPs are used in photodynamic
therapy used for cancer therapy. They are used as a
replacement for photosensitizer, which is excited by
radiation to induce Reactive oxygen species (ROS) genera‐
tion and thus apoptosis [11, 12]. Cerium oxide NPs are used
in radiation therapy for cancer treatment, in which they
selectively kill irradiated cancer cells while posing no
effects on the surrounding normal cells [13]. Zinc oxide NPs
are also used for selective cytotoxicity towards cancer cells,
where they show cytotoxicity by zinc-dependent protein
activity disequilibrium and ROS induction [14]. Copper
oxide NPs can be easily synthesized using plant extract
such as Ficus religiosa [15] or Acalypha indica [16] and their
synthesis methods are simple, non-toxic and eco-friendly
[17]. The controllable pores of silica NPs make them a good
carrier for drugs in anticancer therapy [18]. In addition,
gold, silver and platinum NPs, known as precious metal or
noble metal NPs, are also being used for cancer therapy as
drug delivery and therapeutic agents [8]. The low reactive
nature of these noble elements is advantageous for drug
delivery purposes.
Among all these NPs, zinc oxide NPs are showing promis‐
ing application and efficacy in cancer therapy due to their
highly selective nature and potency towards cancer cells.
This review aims to explore these unique properties of ZnO
NPs, their role in the human body and their mechanism of
cytotoxicity towards cancer cells.
2. ZnO Nanoparticles
Nanotechnology deals with controlling, modifying and
fabricating materials, structures and devices with nanome‐
tre precision. It helps to understand the fundamental
physics, chemistry, biology and technology of nanometre-
scale objects [19]. ZnO nanoparticles are nano-sized
particles of ZnO with a size less than 100 nm. They can be
prepared by several different methods, such as solid, liquid
(i.e., chemical) and gaseous. There are a variety of chemical
methods, for example mechanochemical process, precipi‐
tation process, precipitation in the presence of surfactant,
sol-gel method, solvo-thermal, hydrothermal, emulsion
and micro-emulsion methods [20]. The chemical method is
the most cost-effective, reliable and environmentally
friendly and also provides flexibility for controlling the size
and shape of synthesized nanoparticles. Nanoparticles
with high surface area to volume ratio are preferred and,
to make these types, stabilization of the nanoparticles is
important. The synthesis of particles in nano size only is not
fruitful in its application as these can again easily agglom‐
erate into macro-sized particles. Therefore, they are
stabilized by using surfactant, polymer molecules, or any
organic molecules bound to the surface of nanoparticles,
for example, Triton-X 100 or PEG. The main significance of
nanoparticles is that the size reduction to nanoscale may
lead to the development of new unique physicochemical,
structural, electronic and magnetic properties of nanopar‐
ticles, which are not present in their macro or bulkier form
[21]. These novel properties are mainly responsible for the
unique and vast application of nanoparticles in the biolog‐
ical and medical field. ZnO nanoparticles now have a wide
range of applications in cancer therapy, biosensing, drug/
gene delivery, nanomachines that can act as biological
mimetic, biomaterials for tissue engineering, shape-
memory polymers such as molecular switches, etc. Owing
to this wide application of ZnO nanoparticles, a variety of
ZnO nanostructures have been synthesized, including
nanoparticles, nanowires, nanorods, nanotubes, nanobelts
and other complex morphologies [22].
2.1 ZnO nanoparticles: Promising for anticancer therapies
A ZnO nanoparticle, as a wide band-gap semiconductor,
can readily absorb UV rays. Owing to this property, ZnO
nanoparticles have a wide range of application, from
electronic devices, cosmetics and facial products to bio‐
medical application. ZnO nanoparticles are now being
widely researched for their anticancerous properties. Some
of the characteristic features of ZnO nanoparticles behind
their surge in anticancer therapy are described below.
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2.1.1 Biocompatibility
ZnO nanoparticles show relatively high biocompatibility.
Their bulkier form is generally recognized as safe (GRAS)
by the FDA. Zinc is an important co-factor in various
cellular mechanisms and plays an important role in
maintaining cellular homeostasis; hence ZnO shows
biocompatibility. The administered ZnO can be easily
biodegraded or can take part in the active nutritional cycle
of the body [23].
2.1.2 Selectivity
ZnO nanoparticles have an inherent nature of showing
selective cytotoxicity against cancerous cells in in vitro
condition compared with other nanoparticles. They can be
further surface engineered to show increased selective
cytotoxicity [24].
2.1.3 Easy synthesis
The synthesis process of ZnO nanoparticles is relatively
easy, with a wide variety of methods. Owing to these
different methods of synthesis, their size and size distribu‐
tion can be easily controlled. Research has shown that the
size of nanoparticles is directly proportional to the toxicity
they show; in addition, size manipulation is significant for
producing greater EPR effect to increase intra-tumour
concentration of nanoparticles [25].
2.1.4 Enhanced cytotoxicity
While extracellular ZnO shows biocompatibility, elevated
levels of administered intracellular ZnO show enhanced
cytotoxicity through zinc-mediated protein activity
disequilibrium and oxidative stress [14]. ZnO nanoparticles
have the unique ability to induce oxidative stress in cancer
cells, which has been found to be one of the mechanisms of
cytotoxicity of ZnO nanoparticles towards cancer cells. This
property is due to the semiconductor nature of ZnO. ZnO
induces ROS generation, leading to oxidative stress and
eventually cell death when the anti-oxidative capacity of
the cell is exceeded [26].
2.2 Key properties of nanoparticles
2.2.1 Size
Size is one of the key properties of nanoparticles. A size
range of 10-100 nm is considered good for biological
application. The lower scale of this size range is based on
the measurement of the sieving coefficient for the glomer‐
ular capillary wall, as the threshold for first pass elimina‐
tion by the kidneys is estimated to be 10 nm in diameter.
The upper scale of the size range is based on the result of
various studies showing that, up to 100 nm, nanoparticles
show better efficacy. Some research articles show that
nanoparticles smaller than 10 nm diameter accumulate
more efficiently and penetrate more deeply in tumours
than their larger counterparts [25], but extensive research
is necessary in this area as nanoparticles smaller than 10 nm
may have a wide range of toxic issues in normal cells and
the overall body. Nano size allows nanoparticles to enter
inside the cell easily and manipulate the cellular function
of the cell, leading to cytotoxicity. Nanoparticles can
interact with biological molecules and manipulate various
cellular cycles, disrupting cellular homeostasis and
inducing apoptosis, due to their small size, which cannot
be checked by the plasma membrane.
Tissue resident macrophage in the liver and spleen rapidly
clears most particles entering into blood vessels. A blood
protein called ‘opsonins’ is adsorbed in any foreign
particles entering blood and macrophage targets these
adsorbed opsonins. Research has suggested that size is
related to blood circulation time of particles. The smaller
the size, the more the blood circulation time. In addition,
small size, i.e., less than 10 nm, shows increased cytotoxic‐
ity by means of increased diffusion through cytoplasm.
These ultra-sized particles even enter the nucleus and show
toxicity through nucleus aberration [25].
2.2.2 High surface area to volume ratio
Nanoparticles have high surface area to volume ratio due
to their nano size. This property of nanoparticles allows
increased surface contact and increased reactivity and
solubility and other wide ranges of application. Various
ligand and targeting molecules can be conjugated in the
surface of nanoparticles, which is an important aspect of
nanoparticle-mediated drug delivery.
The surface charge of a nanoparticle also has an important
effect on its fate. High surface charges lead to increased
macrophage scavenging activity, resulting in rapid clear‐
ance of nanoparticles from blood vessels. Similarly, surface
charge should be maintained in such a way that it should
have minimal self-self and self-nonself interaction while
displaying selectivity towards tumour cells. The ultimate
fate of nanoparticles depends upon their interaction with
their surrounding environment, which ultimately depends
upon the size and surface properties of nanoparticles [27].
The other properties of nanoparticles also include chemical
composition of high purity, crystallinity, and quantum
effects that can affect chemical reactivity.
3. Zinc and Cancer
3.1 Zinc and its role in the human body
Zinc is a silver-grey-coloured transition metal with oxida‐
tion state +2, having five stable isotopes. It is the most
important and abundant trace element in the body after
iron. The total body zinc content has been estimated to be
30 mM (2g). It is required in the human diet in trace
quantities, which is approximately 15 mg Zn per day [28].
It is present in all body tissues and fluid. Zinc plays a major
role in the immune system, affecting a number of aspects
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of humoral and cellular immunity. It helps to maintain cell
and organ integrity by stabilizing the molecular compo‐
nents of membrane and cellular components. Zinc has a
role in regulating a large number of enzymes present in the
body, which later participate in synthesis and degradation
of carbohydrates, lipids, proteins and nucleic acid, as well
as in metabolism of other micronutrients, thus playing a
crucial role in maintaining proper body condition and
homeostasis. It also plays a role in genetic expression by
regulating polynucleotide transcription. Concentration-
dependent absorption of zinc occurs throughout the small
intestine, whereas zinc is lost from the body through the
kidneys, skin and intestines [29].
3.2 Zinc deficiency leads to initiation and progression of cancer
Zinc is the co-factor of over 300 mammalian enzymes and
plays a vital role in host defence against the initiation and
progression of cancer [30]. The tumour suppressor p53
gene and caspase enzyme help to check cells regularly and
prevent them from becoming cancerous. If a cell shows any
kind of malignancy, a DNA repair mechanism is activated
to repair the altered DNA. If this mechanism fails to repair
the DNA, then the cell undergoes ‘programmed cell death’,
known as apoptosis, to prevent the altered cell from
dividing, which may later develop in the cancerous cell. In
one way or another, zinc is involved in all these processes
of protecting cells against cancer.
The exact mechanism for inducing apoptosis is not clear,
but mutation or damage to DNA appears to play a major
role in triggering activation of the p53 gene, which leads to
apoptosis [31]. The specific DNA-binding domain of p53
contains a complex tertiary structure that is stabilized by
zinc [32]. Thus, zinc plays a major role in maintaining the
activity of tumour suppressor gene p53, which regulates
apoptosis activity of cells. Similarly, zinc also plays a crucial
role in the activation of the caspase-6 enzyme, a major
enzyme responsible for apoptosis. Caspase-6 is the most
sensitive apoptosis-related molecular target of zinc. It is
responsible for the activation of caspase-3 and other
enzymes that are responsible for nuclear membrane
dissolution leading to cell death [33]. Several zinc channels
maintain a crucial balance between life and cell death,
controlling the intracellular zinc movements and free
amount of the metal. While low concentration of zinc can
lead to the initiation and progression of cancer, high
concentration of zinc also has a deleterious effect on health.
An excess amount of zinc that exceeds the capacity of the
zinc homeostasis system can lead to a breakdown of the
zinc transporting system of the plasma membrane, result‐
ing in increased intracellular zinc concentration, which
ultimately activates apoptosis, causing cell death [34]. The
deleterious effect of excess zinc is discussed in detail later
in the section “Mechanism of cytotoxicity of ZnO NPs”.
Zinc plays an important role in response to oxidative stress,
DNA replication, DNA damage repair, cell cycle progres‐
sion and apoptosis; hence a deficiency of zinc leads to
disruption of crucial homeostasis in cells. A decrease in
cellular zinc alone causes DNA damage and impairs the
DNA damage response mechanism, resulting in a loss of
DNA integrity and potential for increased cancer risk. It has
been observed that low intracellular zinc induces oxidative
DNA damage, disrupts p53 and affects DNA repair in rat
glioma cell lines [35]. Likewise, an increase in serum
copper/zinc ratios in patients with cancers of the lung,
breast, gastrointestinal tract and gynaecological malignan‐
cy has been observed [36]. In addition, significantly lower
than normal tissue zinc concentration has been demon‐
strated in oesophagus cancer [37]. Similarly, evidence
suggests that zinc accumulation is an important factor in
the progression and development of prostate cancer, often
characterized by low zinc concentration in malignant
prostate cells as a result of downregulation of ZIP 1, a zinc
transporter protein [38].
All these research findings suggest that cancerous cells are
characterized by a decrease in zinc concentration or altered
zinc concentration. A deficiency of zinc can make cells
unstable and prone to cancer. It is an important factor in the
development and progression of malignancy. Therefore,
zinc-mediated cancer chemoprevention could be effica‐
cious in the prevention and treatment of several cancers.
4. Interaction of Nanoparticles with Biological
Components
Nanoparticles act on a nano level. Therefore, understand‐
ing the interaction of nanoparticles with the cell surface is
important in understanding the mechanism of their action
and manipulating it for medical and biological application.
Nano-bio interface is a dynamic physicochemical interac‐
tion between the nanomaterial surface and the surface of
biological components, which deals with the kinetic and
thermodynamic exchanges between the interface [39]. It
includes the interaction between the nanoparticles’ surfa‐
ces, the solid-liquid interface and the solid-liquid interface
contact zone with the biological membrane.
Besides the nano-bio interface, another important interac‐
tion that defines the role of nanoparticles is the interaction
between nanoparticles themselves. Various forces, such as
van der Waals forces, electrostatic force, solvation, solvo‐
phobic and depletion forces act on these interactions, which
affect the rate of agglomeration of nanoparticles in media
[40]. An understanding of this interaction is important for
the proper dispersal of nanoparticles in the media with
minimal agglomeration. Furthermore, the use of optimal
surfactants and polymers to stabilize nanoparticles can be
found by studying these interactions.
Van der Waals and depletion forces act as attractive forces,
whereas electrostatic force acts as a repulsive force. Van der
Waals forces arise from changes in the dipole moment of
electrons, which induce a dipole moment in the adjacent
atoms. It arises from the quantum mechanical dance of
electrons [41]. These different forces play an important role
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in the adhesive interaction of nanoparticles in the cell
surface and their passive uptake inside the cell [42, 43].
Their passive uptake inside the cell. This adhesive interac‐
tion to the cell surface is favored by the optimizable surface
area of nanoparticles according to the cell surface receptor,
and the comparative size of nanoparticles to that of ligands/
biomolecules, leading to adhesive interaction and passive
uptake inside the cell, boycotting the phagocytic process
[44, 45]. With this passive uptake, nanoparticles can directly
interact with cytoplasm proteins and cell organelles,
leading to increased cytotoxicity. They can localize any‐
where inside the cell including the outer membrane,
cytoplasm, lipid vesicles, mitochondria, nuclear mem‐
brane, nucleus, DNA, etc., damaging these cell organelles
and ultimately leading to cell death [46].
4.1 Protein corona determines the fate of nanoparticles
The fate of a nanoparticle, i.e., the biological area that it will
target, is known to be dependent upon the nature of the
particle  itself,  i.e.,  its  hydrophobicity,  size,  radius  of
curvature, charge, coatings, etc. These factors influence the
protein coating that is formed around nanoparticles when
it enters a biological fluid. This coated-protein structure of
nanoparticles is called a protein corona. The coated protein
may  undergo  conformational  change,  leading  to  the
exposure of  new epitopes and altered function.  Protein
corona interacts with certain biological membranes while
showing  no  interaction  with  certain  other  biological
membranes. It shows specificity, thus determining the fate
of nanoparticles. Protein binding to nanoparticles also helps
to increase the dissolution rate of nanoparticles [47, 48].
Figure 1. A pictorial representation of the formation of a protein corona
when nanoparticles are exposed to serum. This figure represents the
interaction of nanoparticles once they are injected inside the body.
Biomolecules, especially protein, form a thin layer of segment around the
surface of nanoparticles, known as a protein corona. High-affinity proteins
(green) bind tightly with the nanoparticle surface, forming a first layer of
hard corona followed by the reversible adsorption of low-affinity protein
forming a soft corona. (Figure taken from research article “Verderio P,
Avvakumova S, Alessio G, Bellini M, Colombo M, Galbiati E, et al.
Delivering Colloidal Nanoparticles to Mammalian Cells: A Nano–Bio
Interface Perspective. Advanced Healthcare Materials. 2014;3[7]:957-76.”
Licence granted by John Wiley and Sons under partnership with copyright
clearance centre for the reuse of above figure. Licence Number:
3850911134439).
As depicted in Figure 1, a protein corona forms once
nanoparticles are injected inside the body, where it inter‐
acts with serum biomolecules, especially protein. High-
affinity proteins bind tightly with the nanoparticle surface,
forming a first layer of hard corona followed by the
reversible adsorption of low-affinity protein, forming an
additional layer of soft corona [49]. The nature of nanopar‐
ticles, such as size, charge, hydrophobicity, etc., contributes
to the formation of the corona. Various interactions take
place between the corona and the surrounding environ‐
ment and the corona dynamically changes. These interac‐
tions include steric hindrance, protein binding capability,
available surface area, binding interaction and characteris‐
tic protein attachment/detachment. Steric hindrance
prevents binding of the corona to other particles. The
available surface area, surface coverage and angle of
curvature determine the adsorption profile of nanoparti‐
cles. Binding interaction releases surface-free energy,
leading to surface reconstruction of the corona. Competi‐
tive binding interaction depends upon protein composition
and body fluid composition. Characteristic protein attach‐
ment/detachment depends upon the material type and
protein characteristic. All these interactions help to change
the corona dynamically. The corona changes when parti‐
cles translocate from one biological compartment to
another. In the process of formation of the protein corona,
when the protein interacts with nanoparticles, they
undergo potential changes in their structure and function.
Basically, protein conformational change takes place,
leading to protein fibrillation, loss of enzymatic activity,
protein crowding, etc., and surface opsonization of the
corona takes place, allowing additional nano-bio interac‐
tion.
Thus, the nanoparticle-protein corona interaction is
important for understanding the surface properties,
charge, resistance to aggregation, hydrodynamic size,
specificity and biological targets of nanoparticles [48], and
these factors play an important role in the cellular uptake
and subcellular localization of nanoparticles [50].
5. Mechanism of Cytotoxicity
The basic mechanism behind the cytotoxicity of ZnO NPs
is the intracellular release of dissolved zinc ions, followed
by ROS induction. This event causes zinc-mediated protein
activity disequilibrium and oxidative stress, eventually
killing the cell. Soluble extracellular zinc shows very little
cytotoxicity. Recent research shows that extracellular
soluble zinc, when exposed to cell culture and media, forms
poorly soluble amorphous zinc-carbonate phosphate
precipitates (phosphate from media). This precipitate is
supposed to protect the cell from the cytotoxicity of zinc
[51]. On the other hand, with the release of soluble zinc ions
inside the cell, a cascade of pathways interrelated to each
other takes place, which is responsible for the cytotoxic
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response of the ZnO nanoparticles. These events can be
described in three major topics, as follows:
5.1 Zinc-mediated protein activity disequilibrium
Zinc is the one of the major trace elements found in the
human body and is maintained in a definite concentration
inside a cell [52]. Alteration in this concentration of zinc in
the cell may cause severe problems in various cellular
processes, as zinc is the co-factor of more than 300 mam‐
malian enzyme [30]. With the application of ZnO NPs and
the intracellular release of zinc ions, the concentration of
zinc in the cell rises from normal level, resulting in zinc-
mediated protein activity disequilibrium. This affects a
wide range of crucial cellular processes, including DNA
replication, DNA damage repair, apoptosis, oxidative
stress, electron transport chain, cellular homeostasis, etc.,
rendering cytotoxicity towards the cell [14].
Figure 2. A schematic representation of the mechanism of cytotoxicity of a
nanoparticle. (Figure taken from open source article “Shen C, James SA, de
Jonge MD, Turney TW, Wright PF, Feltis BN. Relating cytotoxicity, zinc ions,
and reactive oxygen in ZnO nanoparticle-exposed human immune cells.
Toxicol Sci. 2013;136[1]:120-30”. Licence granted by Oxford University Press
under partnership with copyright clearance centre for the reuse of above
figure. Licence Number: 3850790022302 ).
As illustrated in Figure 2 above, first of all ZnO nanoparti‐
cles are taken up by the cell through endocytosis. Some
nanoparticles simply enter the cell, whereas some enter
through pinocytosis and phagocytosis bounded by endo‐
somes and lysosomes. As pH decreases, the ZnO nanopar‐
ticles’ dissolution rate increases rapidly, causing lysosome
destabilization [53]. The pH of early endosome is relatively
low, i.e., 6.3, which favours the release of soluble zinc ions.
It further decreases to pH 5.5 at late endosome and pH 4.7
in lysosome, where a rapid dissolution rate of ZnO NPs is
observed, causing lysosome destabilization. This suggests
that, for the release of zinc ions, low pH is necessary and
thus the release of zinc ions in blood or extracellular fluid,
which has a normal pH of 7, is not favourable [14]. This
process leads to an increased release of soluble zinc ions
inside the cell. The increase in intracellular zinc concentra‐
tion leads to zinc-dependent protein activity disequilibri‐
um, thus resulting in cytotoxicity to the cell. The increase
in soluble zinc ions also increases ROS concentration,
leading to cytotoxicity of cells through oxidative stress [54].
5.2 ROS production and oxidative stress
ROS, a reactive species of molecular oxygen, is produced
inside the cell during various cellular processes, including
mitochondrial respiration, inflammatory response, micro‐
some activity, peroxisome activity, etc. It acts as a biomo‐
lecule and plays an important role in cell signalling and
homeostasis. Exogenously, ROS is induced in response to
various stimuli including nanomaterials [55]. ROS is
induced by ZnO NPs in two ways. One is due to the pro-
inflammatory response of the cell against nanoparticles [56]
and the other is due to the characteristic surface property
of ZnO NPs that makes them a redox reaction system
producing ROS [26, 57].
The ability to induce oxidative stress through ROS gener‐
ation by ZnO nanoparticles is due to its semiconductor
properties. ZnO is a wide band-gap semiconductor with
direct band-gap of 3.37 eV and large excitation binding
energy of 60 MeV [58]. Being a semiconductor, it does not
have a continuum band of electronic states like other metal.
The valence band and conduction band are separated by a
considerable large energy gap, i.e., 3.37 eV. Normally, UV
light is required to elucidate electrons (e-) from the valence
band to reach the conduction band, leaving holes (h+) in the
valence band. Conduction of electricity takes place by the
movement of free electrons in the valence band. However,
in the case of the nano-sized ZnO nanoparticles, electrons
also jump to the conduction band in the absence of UV
irradiation [59]. Electrons and holes often recombine
quickly but in the case of nanoparticles, they move to the
nanoparticle surface, where they react with the adsorbed
species. This results in an increased number of electrons
and holes in the nanoparticle surface. This peculiar char‐
acteristic of nanoparticles may be due to the crystal defect
in nanoparticles, due to their nano size.
Holes (h+) act as a powerful oxidant, breaking water
molecules into hydrogen and hydroxyl ions. Similarly,
electrons act as a powerful reducer, reacting with adsorbed
and dissolved oxygen molecules, generating superoxide
radical anions (O2−). These superoxide radical anions
further react with hydrogen ions, producing HO2− radicals,
which further react to create H2O2. All these radicals are a
highly reactive oxygen species known as ROS, which acts
as a strong oxidizing agent. Accumulation of these species
in great amounts leads to a misbalance in the oxidative-
reductive homeostasis of the cell, leading to oxidative
stress, which is very harmful to the cell and eventually
causes cell death. Thus, holes and electrons in ZnO nano‐
particles act as a redox reaction system, producing a
reactive oxygen species and thus increasing oxidative
stress in the cell [26].
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5.3 DNA damage and apoptosis
With elevated levels of ROS and oxidative stress, ZnO NPs
show a deleterious effect on the lipid, protein and nucleic
acid of the cell [60]. Elevated ROS can cause membrane
damage through lipid peroxidation and protein denatura‐
tion, resulting in cell death by necrosis and DNA damage,
resulting in cell  death by apoptosis  [55].  DNA damage
mainly occurs by DNA strand breaks and DNA protein
cross-links [61, 62]. Highly reactive species of ROS can react
with components of DNA, altering DNA composition and
bringing mutation in DNA. OH radical, a highly reactive
species of oxygen, causes single stranded breakage in DNA
via  the  formation  of  8-hydroxy-2-deoxyguanosine  (8-
OHdG)  DNA  adduct  [63].  These  DNA  breakages  and
crosslinks  damage DNA,  leading to  the  activation of  a
mitochondrial apoptotic pathway, eventually causing cell
death by apoptosis  [31].  Apoptosis,  a  programmed cell
death, is believed to be the major mechanism of cell death
in this cytotoxic response of ZnO NPs [64, 65].
Figure 3. A schematic representation of the overall cytotoxicity of ZnO
nanoparticles, leading to cell death
Figure 3 shows the overall mechanism of cytotoxicity of
ZnO NPs. As represented in the figure, zinc-dependent
protein activity disequilibrium and elevated ROS produc‐
tion leads to cytotoxicity. Research into ROS has shown
that the use of antioxidants and ROS quenchers did not
significantly decrease the cytotoxicity of ZnO NPs [14, 51,
54]. This suggests that ROS production might not be the
main mechanism of cytotoxicity of ZnO NPs, but rather
the  cytotoxic  response  instead.  Although  ROS  is  also
produced by the interaction of ZnO with the cell, the main
source of  ROS production may be due to the cytotoxic
response of zinc-dependent protein activity disequilibri‐
um,  such  as  the  permeabilization  of  mitochondria
releasing huge amounts of ROS in the cell. This leads to
the  conclusion  that  the  probable  main  mechanism  of
cytotoxicity of ZnO NPs is zinc-dependent protein activity
disequilibrium as a result of the increased dissolution of
free zinc ions inside the cell [14, 51, 54].
6. Selective Cytotoxicity Towards Cancer Cells
Many in vitro studies have proved that ZnO NPs show
selective cytotoxicity towards cancer cells [66-70]. Hanley
suggested that they show 28-35 times selective toxicity
towards cancer cells compared with that of normal cells
[24]. This selective cytotoxicity in cancer cells in in vitro
condition can also be further exploited in the in vivo
condition by selectively targeting ZnO nanoparticles
towards cancer cells. ZnO NPs selectively kill cancer cells
by inferring selective localization and selective cytotoxicity
towards them.
6.1 Selective localization through EPR and electrostatic
interaction
One of the characteristics of nanoparticles is that they show
enhanced permeation and retention effect (EPR) in tumour
cells because of their small size and surface properties. Due
to the rapid and uncontrolled growth of tumours, tumour
cells lack properly developed blood and lymphatic vessels.
Cell-cell connections in a tumour cell are also weak due to
an improperly developed tight junction. Blood vessels
running through a tumour have pores ranging in size from
100 nm to 1 micrometre. Owing to these properties of
cancer cells, nanoparticles can easily diffuse through the
blood vessels towards a tumour cell, thus showing en‐
hanced permeation selectively toward tumor cell. This
process of movement of nanomaterials from blood to the
tumour bulk is called extravasation. The extravasated
fluids and particles are quickly carried away by the flow of
interstitial fluid surrounding the cell, known as lymph in
healthy tissue. However, since a tumour cell also has an
improper lymphatic system, they are not carried away from
the tumour tissue, immediately allowing enhanced
retention time for nanoparticles in tumour tissues. The
enhanced retention time allows enhanced diffusion of
particles inside the tumour cell. Thus, the enhanced
permeation and retention effect helps nanoparticles to be
localized specifically in the tumour cell specifically and to
act upon it [26, 27].
The electrostatic characteristic of ZnO nanoparticles is also
useful for anticancer therapy as a selective targeting
purpose. ZnO has a neutral hydroxyl group attached to its
surface, which plays an important role in its surface charge
behaviour. At high pH, ZnO exists as ZnO− due to the
transfer of adsorbed protons from its surface towards
aqueous solution. At low pH (acidic condition), ZnO exists
as ZnOH2+ due to the transfer of protons from the aqueous
environment towards its surface. The isoelectric pH of ZnO
nanoparticles is 9-10. Thus, ZnO nanoparticles exhibit
positive charge under physiological conditions such as
blood or tissue fluid (which has pH 7), etc. [26, 71]. On the
other hand, cancerous cells usually have high concentra‐
tion of (negatively charged) anionic phospholipids on their
outer membrane [72]. This leads to an electrostatic attrac‐
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tion between ZnO nanoparticles and cancerous cells,
thereby promoting selective localization, cellular uptake,
phagocytosis and finally cytotoxicity. Selective localization
of NPs can be further enhanced by proper surface engi‐
neering and modification.
6.2 Selective cytotoxicity through ROS
While many studies have demonstrated that ZnO NPs
show selective cytotoxicity towards cancer cells, the exact
mechanism of the selectivity is still unclear. ROS may
provide a possible explanation for the selective cytotoxic
response of ZnO NPs towards proliferating cells. It has
been observed that ROS generation is relatively greater in
cancer cells than in normal cells after ZnO NP treatment
[66]. ROS and various signalling molecules are generally
found in greater amount in rapidly proliferating cells such
as cancer cells, owing to their faster metabolism rate
compared with normal cells [73]. When ZnO NP treatment
is given to cancer cells, then ZnO nanoparticles, being a
redox reaction system in themselves, may react with the
increased amount of chemical species and signalling
molecules around them, producing even more ROS,
resulting in huge oxidative stress in the cell and eventually
killing the cell. While ZnO NP treatment also generates
ROS in normal cells, the generation is relatively low
compared with cancer cells, as initially they have less ROS
and fewer signalling molecules that can be converted into
more reactive species. Hence, the oxidative stress produced
may not be enough to kill the cell and thus it shows a
relatively lower cytotoxic response. This may, therefore, be
the possible mechanism behind the selective cytotoxicity of
ZnO NPs in proliferating cells, including cancer cells.
7. Conclusion
Nanoparticles, with their unique properties, are showing
increasing application in cancer research and therapy. With
their selective targeting property and usefulness as a carrier
agent, ZnO NPs can be good substitutes for traditional
cancer therapy. This review has mainly focused on ZnO
NPs, the relation between zinc and cancer, zinc’s role in the
human body and the probable mechanism surrounding
ZnO NPs with the biology of the human body, leading to
its selective localization and cytotoxicity towards cancer
cells. While ZnO NPs induce cytotoxicity towards cancer
cells through oxidative stress via ROS generation, this may
not be the main mechanism of cytotoxicity; rather, the
response of zinc-mediated protein activity disequilibrium
as a result of high levels of intracellular zinc ions is a more
likely cause.
Nanoparticles in medicine are a new and emerging topic of
interest for researchers. With all their promising character‐
istics, the in vivo application of nanoparticles is still rare
and there is currently a serious lack of in vivo research into
nanoparticles. Hence, a much better collaboration between
clinicians, biologists and material scientists is required for
the in-depth understanding of cancer biology and intelli‐
gent design of NPs for their better clinical use. A dynamic
collaboration could lead to the development of smart NPs
that show superior accuracy of selectivity and toxicity
towards cancer cells while causing no harm to normal cells.
This is in fact an achievable aim, considering the highly
promising characteristics of ZnO NPs and their inherent
nature of selectivity and toxicity towards cancer cells,
making them unequivocally a key tool for next-generation
cancer treatment.
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